Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)

M. Yasuda, E. Kimura, K. Ochiai, S. Tada, Y. Udagawa, Daisuke Aoki, S. Nozawa, Y. Kikuchi, T. Kita, M. Nishida, H. Tsunoda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We conducted a dose-finding study for combination therapy of paclitaxel (Taxol; TXL) and carboplatin (Paraplatin; CBDCA). TXL is a novel plant-derived anticancer agent that is a diterpene derivative possessing the taxane ring. The subjects were patients with ovarian carcinoma, who were evaluated by a modified Fibonacci method. The dosage of TXL was 150 to 180 mg/m2. CBDCA was administered by dose escalation from AUC = 4 to 7. The administration schedule was as follows. Pre-medication was administered before TXL was given. TXL was then administered by intravenous infusion over 3 hours, followed by CBDCA. The dose of CBDCA was determined using the Calvert formula: [AUCX (GFR + 25)]. GFR was calculated with the Jelliffe equation. The non-hematological toxicities observed in 15 eligible cases were mainly grade 1, with no grade 3 or above, and no increase in severity was observed with stepping up. The hematological toxicities were grade 3 leukopenia in 5 of 15 cases, neutropenia in 5 cases and thrombocytopenia in 0 cases. No grade 4 toxicity was observed. The lowest counts of leukocytes and neutrophils were reached after 10.8 and 11.7 days, respectively. The toxicities were reversible in most cases with subsequent recovery. The above findings indicate that the recommended dosages for TJ therapy for Japanese ovarian cancer patients should be TXL 180 mg/m2 and CBDCA at a target of AUC = 6.

Original languageEnglish
Pages (from-to)493-498
Number of pages6
JournalJapanese Journal of Cancer and Chemotherapy
Volume28
Issue number4
Publication statusPublished - 2001 Apr
Externally publishedYes

Fingerprint

Carboplatin
Paclitaxel
Ovarian Neoplasms
Area Under Curve
Diterpenes
Leukopenia
Neutropenia
Leukocyte Count
Intravenous Infusions
Thrombocytopenia
Antineoplastic Agents
Appointments and Schedules
Neutrophils
Carcinoma
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Yasuda, M., Kimura, E., Ochiai, K., Tada, S., Udagawa, Y., Aoki, D., ... Tsunoda, H. (2001). Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB). Japanese Journal of Cancer and Chemotherapy, 28(4), 493-498.

Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB). / Yasuda, M.; Kimura, E.; Ochiai, K.; Tada, S.; Udagawa, Y.; Aoki, Daisuke; Nozawa, S.; Kikuchi, Y.; Kita, T.; Nishida, M.; Tsunoda, H.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 28, No. 4, 04.2001, p. 493-498.

Research output: Contribution to journalArticle

Yasuda, M, Kimura, E, Ochiai, K, Tada, S, Udagawa, Y, Aoki, D, Nozawa, S, Kikuchi, Y, Kita, T, Nishida, M & Tsunoda, H 2001, 'Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)', Japanese Journal of Cancer and Chemotherapy, vol. 28, no. 4, pp. 493-498.
Yasuda, M. ; Kimura, E. ; Ochiai, K. ; Tada, S. ; Udagawa, Y. ; Aoki, Daisuke ; Nozawa, S. ; Kikuchi, Y. ; Kita, T. ; Nishida, M. ; Tsunoda, H. / Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB). In: Japanese Journal of Cancer and Chemotherapy. 2001 ; Vol. 28, No. 4. pp. 493-498.
@article{b7e2e23881ab49b392223585d9d46924,
title = "Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)",
abstract = "We conducted a dose-finding study for combination therapy of paclitaxel (Taxol; TXL) and carboplatin (Paraplatin; CBDCA). TXL is a novel plant-derived anticancer agent that is a diterpene derivative possessing the taxane ring. The subjects were patients with ovarian carcinoma, who were evaluated by a modified Fibonacci method. The dosage of TXL was 150 to 180 mg/m2. CBDCA was administered by dose escalation from AUC = 4 to 7. The administration schedule was as follows. Pre-medication was administered before TXL was given. TXL was then administered by intravenous infusion over 3 hours, followed by CBDCA. The dose of CBDCA was determined using the Calvert formula: [AUCX (GFR + 25)]. GFR was calculated with the Jelliffe equation. The non-hematological toxicities observed in 15 eligible cases were mainly grade 1, with no grade 3 or above, and no increase in severity was observed with stepping up. The hematological toxicities were grade 3 leukopenia in 5 of 15 cases, neutropenia in 5 cases and thrombocytopenia in 0 cases. No grade 4 toxicity was observed. The lowest counts of leukocytes and neutrophils were reached after 10.8 and 11.7 days, respectively. The toxicities were reversible in most cases with subsequent recovery. The above findings indicate that the recommended dosages for TJ therapy for Japanese ovarian cancer patients should be TXL 180 mg/m2 and CBDCA at a target of AUC = 6.",
author = "M. Yasuda and E. Kimura and K. Ochiai and S. Tada and Y. Udagawa and Daisuke Aoki and S. Nozawa and Y. Kikuchi and T. Kita and M. Nishida and H. Tsunoda",
year = "2001",
month = "4",
language = "English",
volume = "28",
pages = "493--498",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "4",

}

TY - JOUR

T1 - Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)

AU - Yasuda, M.

AU - Kimura, E.

AU - Ochiai, K.

AU - Tada, S.

AU - Udagawa, Y.

AU - Aoki, Daisuke

AU - Nozawa, S.

AU - Kikuchi, Y.

AU - Kita, T.

AU - Nishida, M.

AU - Tsunoda, H.

PY - 2001/4

Y1 - 2001/4

N2 - We conducted a dose-finding study for combination therapy of paclitaxel (Taxol; TXL) and carboplatin (Paraplatin; CBDCA). TXL is a novel plant-derived anticancer agent that is a diterpene derivative possessing the taxane ring. The subjects were patients with ovarian carcinoma, who were evaluated by a modified Fibonacci method. The dosage of TXL was 150 to 180 mg/m2. CBDCA was administered by dose escalation from AUC = 4 to 7. The administration schedule was as follows. Pre-medication was administered before TXL was given. TXL was then administered by intravenous infusion over 3 hours, followed by CBDCA. The dose of CBDCA was determined using the Calvert formula: [AUCX (GFR + 25)]. GFR was calculated with the Jelliffe equation. The non-hematological toxicities observed in 15 eligible cases were mainly grade 1, with no grade 3 or above, and no increase in severity was observed with stepping up. The hematological toxicities were grade 3 leukopenia in 5 of 15 cases, neutropenia in 5 cases and thrombocytopenia in 0 cases. No grade 4 toxicity was observed. The lowest counts of leukocytes and neutrophils were reached after 10.8 and 11.7 days, respectively. The toxicities were reversible in most cases with subsequent recovery. The above findings indicate that the recommended dosages for TJ therapy for Japanese ovarian cancer patients should be TXL 180 mg/m2 and CBDCA at a target of AUC = 6.

AB - We conducted a dose-finding study for combination therapy of paclitaxel (Taxol; TXL) and carboplatin (Paraplatin; CBDCA). TXL is a novel plant-derived anticancer agent that is a diterpene derivative possessing the taxane ring. The subjects were patients with ovarian carcinoma, who were evaluated by a modified Fibonacci method. The dosage of TXL was 150 to 180 mg/m2. CBDCA was administered by dose escalation from AUC = 4 to 7. The administration schedule was as follows. Pre-medication was administered before TXL was given. TXL was then administered by intravenous infusion over 3 hours, followed by CBDCA. The dose of CBDCA was determined using the Calvert formula: [AUCX (GFR + 25)]. GFR was calculated with the Jelliffe equation. The non-hematological toxicities observed in 15 eligible cases were mainly grade 1, with no grade 3 or above, and no increase in severity was observed with stepping up. The hematological toxicities were grade 3 leukopenia in 5 of 15 cases, neutropenia in 5 cases and thrombocytopenia in 0 cases. No grade 4 toxicity was observed. The lowest counts of leukocytes and neutrophils were reached after 10.8 and 11.7 days, respectively. The toxicities were reversible in most cases with subsequent recovery. The above findings indicate that the recommended dosages for TJ therapy for Japanese ovarian cancer patients should be TXL 180 mg/m2 and CBDCA at a target of AUC = 6.

UR - http://www.scopus.com/inward/record.url?scp=0035321538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035321538&partnerID=8YFLogxK

M3 - Article

C2 - 11329783

AN - SCOPUS:0035321538

VL - 28

SP - 493

EP - 498

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 4

ER -